Video Experimental Relacionado

Updated: May 5, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Duración de la anticoagulación después de la tromboembolía venosa: un metanálisis

David Ost¹, Josh Tepper, Hanako Mihara

¹Center for Pulmonary and Critical Care Medicine, North Shore University Hospital, Manhasset, NY 11030, USA. dost@nshs.edu

|August 11, 2005

Resumen

La anticoagulación extendida reduce significativamente el riesgo de tromboembolismo venoso recurrente (TEV). Si bien los beneficios persisten después de interrumpir el tratamiento, el efecto protector disminuye, lo que indica que la anticoagulación prolongada ofrece una protección sostenida contra la TEV.

Área de la Ciencia:

Cardiología Cardiología.
Hematología Hematología.
La medicina clínica es la medicina clínica.

Sus antecedentes:

Los pacientes con tromboembolismo venoso (TEV) se enfrentan a un alto riesgo de eventos recurrentes.
La duración óptima de la terapia anticoagulante para la TEV es un tema de debate en curso.

Objetivo del estudio:

Revisar sistemáticamente la evidencia existente sobre la prolongación de la duración de la anticoagulación en pacientes con TEV.
Cuantificar los riesgos y beneficios comparativos de la terapia anticoagulante prolongada.

Principales métodos:

Se realizó una búsqueda exhaustiva de la literatura en las principales bases de datos (PubMed, EMBase, Cochrane) y registros de ensayos clínicos.
Se incluyeron ensayos controlados aleatorios publicados entre 1969 y 2004, centrados en la ETV recurrente como resultado.
La extracción de datos y la evaluación de la calidad fueron realizadas de forma independiente por dos revisores, con un tercer revisor que juzgaba los desacuerdos.

Principales resultados:

La anticoagulación prolongada redujo significativamente el riesgo de TEV recurrente en comparación con la terapia a corto plazo (IRR 0,21).
Se observó un beneficio reducido, pero aún significativo, en la prevención de TEV recurrente incluso después de suspender la anticoagulación a largo plazo (IRR 0,69).
El riesgo de eventos hemorrágicos mayores fue comparable entre los grupos de anticoagulación a largo y corto plazo.

Conclusiones:

La anticoagulación prolongada proporciona protección contra la recurrencia de TEV durante el período de tratamiento.
Se observa un efecto protector residual contra la TEV recurrente después del cese de la anticoagulación prolongada.
Los hallazgos apoyan el uso de la anticoagulación extendida para el manejo de TEV, equilibrando la eficacia y la seguridad.

Más Videos Relacionados

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

Videos de Conceptos Relacionados

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...